Your session is about to expire
← Back to Search
Virtual Reality for Sickle Cell Disease
N/A
Recruiting
Led By R. Gentry Wilklerson, MD
Research Sponsored by University of Maryland, Baltimore
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Adult (age > 18 years) emergency department patient
Presenting to the emergency department due to acute pain related to sickle cell disease thought to be due to vaso-occlusive crisis
Must not have
Patients who lack the capacity to provide informed consent
Over the age of 89 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up a single time point 1 hour after the study intervention begins.
Summary
This trial is looking at whether virtual reality can help patients with sickle cell disease who are experiencing vaso-occlusive crises.
Who is the study for?
This trial is for patients with sickle cell disease who are currently experiencing a vaso-occlusive crisis. It's designed to see if virtual reality can help manage their pain alongside the usual treatments they receive.
What is being tested?
The study tests whether using a virtual reality headset and hand-held controllers can reduce pain during a sickle cell crisis, compared to being blindfolded with noise cancellation as an alternative form of distraction.
What are the potential side effects?
Since this trial involves non-invasive methods like virtual reality and sensory deprivation (blindfolding and noise cancelling), side effects may include dizziness or nausea from VR, but generally low risk of harm.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am over 18 years old and currently in the emergency department.
Select...
I am in the emergency department for severe pain from a sickle cell crisis.
Select...
I have a history of sickle cell disease.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am unable to understand or sign the consent form by myself.
Select...
I am over 89 years old.
Select...
I am not currently receiving IV opioids for pain crises.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ a single time point 1 hour after the study intervention ends.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~a single time point 1 hour after the study intervention ends.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Comparison of the change in pain scores between the 3 groups at one hour after completion of the study intervention.
Secondary study objectives
Compare the total duration of Emergency Department treatment measured from the time of delivery of the first intervention to the time of disposition.
Comparison of the change in pain scores between the 3 groups at completion of the study intervention.
Comparison of the change in pain scores between the 3 groups at one hour after study intervention begins.
+3 moreTrial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: Passive Immersive Virtual RealityExperimental Treatment1 Intervention
Patient with sickle cell disease experiencing acute vaso-occlusive crisis randomized to this arm will participate in a passive immersive application on the virtual reality headset with hand-held controllers. The passive immersive application will not allow the user to interact directly with the application or move through the virtual environment .The patient will be able to use the passive immersive application on the device for a maximum of two hours.
Group II: Active Immersive Virtual RealityExperimental Treatment1 Intervention
Patient with sickle cell disease experiencing acute vaso-occlusive crisis randomized to this arm will participate in an active immersive application on the virtual reality headset with hand-held controllers. The active immersive application will allow the user to interact directly with the application and move through the virtual environment .The patient will be able to use the active immersive application on the device for a maximum of two hours.
Group III: Blindfold and Ear PlugsPlacebo Group1 Intervention
Patient with sickle cell disease experiencing acute vaso-occlusive crisis randomized to this arm will wear a blindfold and ear plugs. The patient will be able to remain blindfolded and earplugs for a maximum of two hours.
Find a Location
Who is running the clinical trial?
University of Maryland, BaltimoreLead Sponsor
713 Previous Clinical Trials
379,462 Total Patients Enrolled
R. Gentry Wilklerson, MDPrincipal InvestigatorU of Maryland, Baltimore
Share this study with friends
Copy Link
Messenger